ClinicalTrials.gg
Not yet recruitingNCT06897319TRACH2OUpdated Nov 19, 2026

High-Flow Tracheal Therapy on Tracheobronchial Secretions in Tracheostomized Patients

An interventional study of High-Flow Tracheal Therapy in Tracheostomized Patients, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Not yet recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 19, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This monocentric, randomized crossover study aims to assess the impact of high-flow tracheal therapy (HFT) on the rheological properties of tracheobronchopulmonary secretions in tracheostomized patients. The primary objective is to compare the viscoelastic characteristics of secretions collected with and without HFT. Secondary objectives include evaluating the effects of HFT on dyspnea, patient comfort, and secretion appearance. The study will take place at Cliniques Universitaires Saint-Luc, with adult tracheostomized patients undergoing standard care.

02

Conditions studied

  • Tracheostomized Patients
03

In context

Lead sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain is the lead sponsor of 350 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years old)
  • Tracheostomized patients
  • Patients requiring routine tracheal suctioning and already using HFT overnight

Exclusion criteria

Exclusion Criteria:

  • Insufficient secretions for analysis
  • Cognitive impairment or confusion
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    HFT

    Device: High-Flow Tracheal Therapy

  • No intervention
    Control

Interventions

  • DeviceHigh-Flow Tracheal Therapy

    Device: Airvo 2 (Fisher \& Paykel Healthcare) Settings: Flow rate start at 40L/min and will be adapted according to tolerance; temperature aimed at 37°C or 34°C according to tolerance, FiO₂ set (if needed) according to SpO2 target values.

06

What researchers measure

Primary outcomes

  1. Critical stress (σc)

    The rheological properties measured using Rheomuco (Rheonova) will be sampled during a suctioning procedure. The critical stress σc = G\*(γc).γc, where G\*(γc) is the viscoelastic modulus measured at the critical strain, is the measured stress at which this transition occurs. See the description of the other rheological outcomes in the secondary outcomes.

    Time frame: Measured three times: at baseline, after one hour, after 4 hours

Secondary outcomes

  1. Dyspnea (modified Borg scale)

    The modified Borg Scale (from 0 : no dyspnea; to 10 : maximal dyspnea) will be used

    Time frame: Measured two times: at baseline and after 4 hours

  2. Patient Comfort (Visual Analog Scale - VAS)

    The VAS (from 0 : extremely comfortable; to 10 : extremely uncomfortable) will be used

    Time frame: Measured two times: at baseline and after 4 hours

  3. Secretion Appearance (Murray Scale)

    The Murray scale define the following secretion appearance: * Mucoid * Mucopurulent * Purulent

    Time frame: Measured two times: at baseline and after 4 hours

  4. Viscoelastic modulus (G*)

    The rheological properties measured using Rheomuco (Rheonova) will be sampled during a suctioning procedure. The ratio of the stress to the strain, the viscoelastic modulus G\* , describes the molecular network force in response to shear. In viscoelastic materials, the viscous dissipation shifts in time the stress response to the imposed strain, which is quantified by the damping ratio tan δ. Both G\* and tan δ provide the viscous and elastic moduli, G' and G''. See the description of the other rheological outcomes in the secondary outcomes.

    Time frame: Measured three times: at baseline, after one hour, after 4 hours

  5. Damping ratio (tan δ)

    The rheological properties measured using Rheomuco (Rheonova) will be sampled during a suctioning procedure. At given deformation, a damping ratio above 1 would describe a predominantly viscous material (G'' \> G'), i.e. that behaves like a liquid, whereas a damping ratio below 1 denotes a predominantly elastic material (G' \> G''), that exhibits a solid-like behavior.

    Time frame: Measured three times: at baseline, after one hour, after 4 hours

  6. Critical strain (γc)

    The rheological properties measured using Rheomuco (Rheonova) will be sampled during a suctioning procedure. The viscoelastic characteristics are measured at increasing strains, ranging from about 1 % to about 10000 %. At a critical strain value, γc, typically around or above 1000 % for sputa, the G' and G'' curves cross over (the damping ratio overcomes 1). Beyond this critical point, the sample becomes predominantly viscous over elastic (fluid-like) under strain and starts to flow. See the description of the other rheological outcomes in the secondary outcomes.

    Time frame: Measured three times: at baseline, after one hour, after 4 hours

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Jun 2026 → Jan 2027, primary completion Aug 2027 → Jan 2028 and completion Aug 2027 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2025
First posted
Mar 26, 2025
StartEst.
Jan 1, 2027was Jun 2026
Primary completionEst.
Jan 1, 2028was Aug 2027
CompletionEst.
Aug 1, 2028was Aug 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 20, 2026→Jan 1, 2027
Nov 19, 2026
Primary completion
Aug 1, 2027→Jan 1, 2028
Nov 19, 2026
Study completion
Aug 1, 2027→Aug 1, 2028
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Jun 20, 2026→Jan 1, 2027
    Primary completion Aug 1, 2027→Jan 1, 2028
    Study completion Aug 1, 2027→Aug 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06897319
Responsible party
William Poncin, PT, PhD (Principal Investigator, Cliniques universitaires Saint-Luc- Université Catholique de Louvain) — Principal investigator
First posted
Mar 26, 2025
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

William Poncin, PhD
Contact
william.poncin@uclouvain.be
+3227641111
William Poncin, PhD
principal investigator · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion